Citations

Clear

9383 citation(s) found for "Thomas, PS".

Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire
Wong, Sui H. , Abuzaitoun, Rebhi , Cornblath, Wayne T. , Eggenberger, Eric , Khanna, Sangeeta , Deveney, Tatiana , Ehrlich, Joshua R. , Andrews, Chris , Barnett, Carolina , Lott, Lindsey B. De , Wong, Sui Hsien , Eggenberger, Eric R , Andrews, Chris A , Barnett-Tapia, Carolina , De Lott, Lindsey B , Khanna, Sangeeta

Mayo Clinic

Neurology | December 10, 2024 | Volume: 104 | Issue: 1 | Pages: No page available

10.1212/wnl.0000000000210150 | PMID 39657098 Get It

Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
Guan, Li , Torres‐Saavedra, Pedro A. , Zhao, Xiaobei , Major, Michael B. , Holmes, Brittany , Nguyen, Ngan K. , Kumaravelu, Parasakthy , Hodge, Tim , Diehn, Maximilian , Zevallos, Jose P. , Emami, Bahman, Hayward, Michele C. , Sagar, Stephen M. , Morrison, William H. , Schultz, Christopher J. , Jones, Christopher U. , Galloway, Thomas J. , Yom, Sue S. , Kudrimoti, Mahesh , Kim, Harold E., Harris, Jonathan , Le, Quynh‐Thu , Holmes, Brittany J , Zevallos, Jose , Holsinger, F Chris , Emami, Bahman , Jordan, Richard C , Hayward, Michele C , Sagar, Stephen M , Morrison, William , Schultz, Christopher , Caudell, Jimmy J , Jones, Christopher U , Bratman, Scott V , Galloway, Thomas J , Ma, Daniel , Yom, Sue S , Kudrimoti, Mahesh , Kim, Harold E , Harris, Jonathan , Le, Quynh-Thu , Hayes, D Neil , Diehn, Maximillian , Holsinger, F. Christopher , Daniel, J.

Mayo Clinic

Clinical Cancer Research | December 10, 2024 | Volume: 31 | Issue: 9 | Pages: 1615-1624

10.1158/1078-0432.ccr-24-2334 | PMID 39656603 Get It

Abstract Purpose: NFE2L2/KEAP1/CUL3 mutations have been validated for radioresistance in cell-based assays and animal models. However, clinical validation of these biomarkers has been challenging because of multimodality treatment regimens. This study aims to investigate the association between NFE2L2/KEAP1/CUL3 mutations and patient outcomes, including local failure, locoregional failure, disease-free survival (DFS), and overall survival, using samples from a phase III trial in which patients were treated with radiation monotherapy at two controlled doses. Patients and Methods: We investigated NFE2L2/KEAP1/CUL3 mutations in 250 randomized patients with T2N0 glottic squamous cell carcinoma receiving definitive radiotherapy in the NRG/RTOG 9512 trial. A total of 119 patients had available biospecimens that were subjected to amplicon-based next-generation sequencing to assess for the presence of NFE2L2/KEAP1/CUL3 mutations without regard to outcomes. Mutations in NFE2L2/KEAP1/CUL3 were assessed blinded to clinical outcomes. Cox models (two-sided α = 0.05) were used to evaluate the association with clinical outcomes, performed by an independent statistical team. Results: Nineteen of 119 patients (16.0%) had NFE2L2/KEAP1/CUL3 mutations. Patient, treatment, and tumor characteristics were similar between those with and without mutations. Patients with mutation compared with those without had significantly more local failure [HR = 3.50; 95% confidence interval (CI), 1.56–7.89; P = 0.0025] and locoregional failure (HR = 3.80; 95% CI, 1.80–8.03; P = 0.0005). DFS was significantly worse for the mutated compared with the nonmutated group in the first 2 years (HR = 2.88; 95% CI, 1.46–5.66; P = 0.0022). The median DFS was shorter in the mutation group (10.3 months) versus those with intact NFE2L2/KEAP1/CUL3 (4.2 years). Conclusions: NFE2L2/KEAP1/CUL3 mutations may predict radiation treatment failure in T2N0 glottic cancer. See related commentary by Rao, p. 1563
Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome
Zoref‐Lorenz, Adi , Witzig, Thomas E. , Cerhan, James R. , Jordan, Michael B. , Witzig, T.E. , Cerhan, James R

Mayo Clinic

Leukemia & Lymphoma | December 10, 2024 | Volume: 66 | Issue: 4 | Pages: 628-636

10.1080/10428194.2024.2436037 | PMID 39656557 Get It

Concordance and Test-Retest Consistency of Sleep Biomarker-Based Neurodegenerative Disorder Profiling
Levendowski, Daniel J. , Walsh, Christine M., Lee‐Iannotti, Joyce , Salat, David H. , Fischer, Corrine, Mazeika, Gandis, Tsuang, Debby W. , Chahine, Lana M. , Walsh, Christine M. , Berka, Chris , Boeve, Bradley F. , Ferini-Strambi, Luigi , Lewis, Simon J.G. , Neylan, Thomas C. , Louis, Erik K. St.

Mayo Clinic

No container title available | December 9, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5111150/v1 Get It

Abstract Biomarkers that aid in early detection of neurodegeneration are needed to enable early symptomatic treatment and enable identification of people who may benefit from neuroprotective interventions. Increasing evidence suggests that sleep biomarkers may be useful, given the bi-directional relationship between sleep and neurodegeneration and the prominence of sleep disturbances and altered sleep architectural characteristics in several neurodegenerative disorders. This study aimed to demonstrate that sleep can accurately characterize specific neurodegenerative disorders (NDD). A four-class machine-learning algorithm was trained using age and nine sleep biomarkers from patients with clinically-diagnosed manifest and prodromal NDDs, including Alzheimer’s disease dementia (AD = 27), Lewy body dementia (LBD = 18), and isolated REM sleep behavior disorder (iRBD = 15), as well as a control group (CG = 58). The algorithm was validated in a total of 381 recordings, which included the training data set plus an additional AD = 10, iRBD = 18, Parkinson disease without dementia (PD = 29), mild cognitive impairment (MCI = 78) and CG = 128. Test-retest consistency was then assessed in LBD = 10, AD = 9, and CG = 46. The agreement between the NDD profiles and their respective clinical diagnoses exceeded 75% for the AD, LBD, and CG, and improved when NDD participants classified Likely Normal with NDD indications consistent with their clinical diagnosis were considered. Profiles for iRBD, PD and MCI participants were consistent with the heterogeneity of disease severities, with the majority of overt disagreements explained by normal sleep characterization in 27% of iRBD, 21% of PD, and 26% of MCI participants. For test-retest assignments, the same or similar NDD profiles were obtained for 88% of LBD, 86% in AD, and 98% of CG participants. The potential utility for NDD subtyping based on sleep biomarkers demonstrates promise and requires further prospective development and validation in larger NDD cohorts.
Nationwide Cross-Sectional Analysis of Mortality Trends in Patients with Sarcoidosis and Non-Ischemic Cardiovascular Disease—The Impact of Gender, Ethnicity, Geographical Location, and COVID-19 Pandemic
Ahmed, Raheel , Ahmed, Mushood , Khlidj, Yehya , Rehman, Obaid Ur , Al-Mukhtar, Laith, Khater, Noha Abou , Gardezi, Syed K M , Rashid, Muhammad, Collins, Peter L. , Jain, Hritvik , Ramphul, Kamleshun , Baig, Mudassar , Kouranos, Vasileios , Paray, Nitish Behary , Sharma, Rakesh , Rashid, Muhammad , Khurram Mustaq Gardezi, Syed , Kouranos, Vasilis , Sharma, Rakesh , Ahmed, Raheel , Khlidj, Yehya , Ahmed, Mushood , Chahal, C. Anwar A.

Mayo Clinic

Journal of Clinical Medicine | December 9, 2024 | Volume: 13 | Issue: 23 | Pages: 7463

10.3390/jcm13237463 | PMID 39685921 Get It

Background and Objectives: The epidemiological data regarding mortality rates of adults with sarcoidosis and non-ischemic cardiovascular disease (CVD) are limited. A retrospective observational analysis was conducted to identify trends and disparities related to sarcoidosis and non-ischemic cardiovascular disease mortality among the adult US population from 1999 to 2022. Methods: We used the Centers for Disease Control and Prevention (CDC) WONDER database to extract death certificate data for the adult US population (≥25 years). The age-adjusted mortality rates (AAMRs) per 100,000 persons were calculated, and annual percent changes (APCs) were determined using Joinpoint. Results: Between 1999 and 2022, 23,642 deaths were identified related to non-ischemic CVD + sarcoidosis. The overall AAMR increased from 0.2 (95% CI, 0.2 to 0.3) in 1999 to 0.5 (95% CI, 0.5 to 0.6) in 2022. Females had a higher AAMR than males (0.6 vs. 0.5). Non-Hispanic (NH) blacks had the highest AAMR, followed by NH whites and Hispanic or Latinos. The southern region had the highest AAMR (0.7: 95% CI, 0.6–0.7), followed by the Midwest (0.6, 95% CI, 0.54–0.669), the Northeast (0.5, 95% CI, 0.5 to 0.6), and the West (0.4; 95% CI, 0.3–0.4). Urban and rural areas had comparable mortality rates (0.5 vs. 0.6). People aged 65+ had the highest AAMRs. Conclusions: The overall mortality rates for non-ischemic CVD and sarcoidosis have increased in the US from 1999 to 2022. Females and NH blacks had higher AAMRs, while a minimal variation was observed based on geographical regions. Early diagnosis and prompt management are the keys to reducing the mortality burden of non-ischemic CVD plus sarcoidosis.
Factors That Limit Evaluation of Velopharyngeal Closure During Nasopharyngoscopy
Snodgrass, Taylor D. , Sitzman, Thomas J. , Chee-Williams, Jessica L. , Temkit, Hamy, Perry, Jamie L. , Sitzman, Thomas J , Chee-Williams, Jessica L , Snodgrass, Taylor , Perry, Jamie L

Mayo Clinic

The Cleft Palate Craniofacial Journal | December 9, 2024 | Volume: 62 | Issue: 2 | Pages: 300-308

10.1177/10556656241304224 | PMID 39648534 Get It

Objective To assess the quality of nasopharyngoscopy video recordings used for velopharyngeal insufficiency (VPI) surgical planning and identify factors that limit evaluation of velopharyngeal closure. Design Prospective observational study. Setting Metropolitan-based hospitals with craniofacial clinics in the United States and Canada. Participants One-hundred and forty-two (142) patients with VPI across 10 hospitals. Assessment(s) Nasopharyngoscopy video recordings used for VPI surgical planning . Main Outcome Measure(s) Ratability of nasopharyngoscopy video recordings, with “ratable” defined as the video (1) visualized the velum, lateral pharyngeal wall, and posterior pharyngeal walls at some point during speech production and (2) contained an oral speech sample at the phrase level or above. Results One-hundred and forty-two (142) nasopharyngoscopy video recordings were obtained from patients undergoing VPI evaluation, of which 59.9% (n=85) were ratable. A multilevel logistic regression model was used to identify factors that influenced the quality of nasopharyngoscopy video recordings. Factors associated with unratable nasopharyngoscopy videos were age ( P =.030), sex ( P =.005*), type of scope camera used ( P =.039), presence of compensatory misarticulations ( P =.008), and a limited speech sample ( P =.040). Conclusions A substantial proportion of nasopharyngoscopy video recordings obtained during VPI evaluation are not sufficient for rating velopharyngeal closure. Lack of ratability could impact the surgery selected to treat VPI. Younger patients, those with limited speech samples, or patients with extensive compensatory articulations may be more successful in completing other VPI imaging techniques, such as videofluoroscopy or magnetic resonance imaging.
A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes
Hirsch, Irl B. , Beck, Roy W. , Marak, Martin Chase , Kudva, Yogish C. , Aktürk, Halis Kaan , Bhargava, Anuj , Codorniz, Kevin , Diner, Jamie, Aleppo, Grazia , Blevins, Thomas , Raskin, Philip, Castorino, Kristin , Manessis, Anastasios , Pickering, David, Weinstock, Ruth S. , Bode, Bruce W. , Nguyen, Quang T., Kipnes, Mark, Ruedy, Katrina J., Desjardins, Donna, Haider, Zehra, Jacobson, Christopher , Klein, Klara R. , O’Malley, Grenye , Church, Mei Mei , Mottalib, Adham , Baran, Jesica D., Kurek, Corey, Rizvi, Shafaq, Donahue, Cassandra, Tamarez, Denisa, Atakov-Castillo, Astrid , Borgman, Sarah, Frey, Sarah, Calhoun, Peter , Group, INHALE-3 Study, Ownby, Jonathan G., Johnson, Joseph H., Ruiz, Adriana, Stephens, Nashia, Maxson, Amanda, Akturk, Halis K., Beatson, Christie , Mason, E E , Wolpert, Howard , Sullivan, Asya, Salhin, Amna, Copple, Tina, Beltran, Stephanie, Ryan, Terri, Levister, Camilla, Ipek, Aslihan, Burke, Christine, Langel, Christine, Bauman, Shannon , Haight, Cristina, Bohr, A., Mottalib, Adham, Salah, Tareq , Badri, Marwa Al, Nguyen, Quang T., Nguyen, Loida, Cordero, Christian, Migliozzi, Brittney, Reid, Corey, Kaur, Ravinder Jeet , Livingood, Daine, Cruse, Dana, Kravarusic, Jelena, Coyne, Kasey, Herrmann, Stefanie, Fronczyk, Evelyn, Manessis, Anastasios, McKillop, Lorcan, Hyatt, Jamie, Patruno, Maria, Castorino, Kristin, Church, Mei Mei, Thorsell, Ashley, Shuirman, Maggie, Cobb, Brandon, Watt, Olivia, Bzdick, Suzan, Casaubon, Luis, Espinosa, Valerie, Pandit, Keta, Perez, Jennifer, Armstrong, Chloe, Martinez-Arredondo, Maritza, Stewart, Ana, Ghorbani, Tahereh, Young, Laura , Donahue, Cassandra, Kass, Alexander, Fulghum, Karla, Raskin, Philip, Jordan, Lin, Shao, Baomei, Hirsch, Irl B., Baran, Jesica, Mandava, Patali, Holod, Rosanna, Kaiserman, Kevin B. , Ulloa, Johanna, Pleitez, Jennifer, Sylvan, Joey, Badgett, Lynn, Frey, Sarah, Mba-Oduwusi, Nnenna, Miller, Paige , Fults, Ashleigh, Pritchard, Rosa, Dolzhenko, E. N. , Gabrielson, Deanna, Brown, Sue A. , Ahmann, Andrew , Bergenstal, Richard M. , Kudva, Yogish C. , Akturk, Halis K , Levy, Carol J , Castorino, Kristin , Steenkamp, Devin W , Weinstock, Ruth S , Hamdy, Osama , Klein, Klara R , Church, Mei Mei , Mottalib, Adham , Calhoun, Peter , Hirsch, Irl B , Aleppo, Grazia , Beck, Roy W , Levy, Carol J. , Nguyen, Quang T., Lee, Scott Jeffery , Buse, John B. , Donahue, Cassandra, Borgman, Sarah, Calhoun, Peter , Group, INHALE-3 Study, Akturk, Halis K., Mason, Emma, Bauman, Shannon, Mottalib, Adham, Dhaver, Shilton , Nguyen, Quang T., Manessis, Anastasios, Castorino, Kristin, Church, Mei Mei, Johnson, Olivia, Coviello, Andrea D. , Donahue, Cassandra, Raskin, Philip, Hirsch, Irl B., Ulloa, Johanna, Frey, Sarah, Miller, Paige, McCarthy, Chris

Mayo Clinic

Diabetes Care | December 6, 2024 | Volume: 48 | Issue: 3 | Pages: 353-360

10.2337/dc24-1832 | PMID 39641970 Get It

OBJECTIVE To evaluate a regimen of inhaled Technosphere insulin (TI) plus insulin degludec in adults with type 1 diabetes, who prestudy were predominately using either an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) with continuous glucose monitoring. RESEARCH DESIGN AND METHODS At 19 sites, adults with type 1 diabetes were randomly assigned to TI plus insulin degludec (N = 62) or usual care (UC) with continuation of prestudy insulin delivery method (N = 61) for 17 weeks. RESULTS Prestudy, AID was used by 48% and MDI by 45%. Mean ± SD HbA1c was 7.57% ± 0.97% at baseline and 7.62% ± 1.06% at 17 weeks in the TI group and 7.59% ± 0.80% and 7.54% ± 0.77%, respectively, in the UC group (adjusted difference 0.11%, 95% CI −0.10 to 0.33, P value for noninferiority = 0.01). HbA1c improved from baseline to 17 weeks by >0.5% (5.5 mmol/mol) in 12 (21%) in the TI group and in 3 (5%) in the UC group and worsened by >0.5% (5.5 mmol/mol) in 15 (26%) in the TI group and in 2 (3%) in the UC group. The most common TI side effect was a brief cough; eight participants discontinued TI due to side effects. CONCLUSIONS In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.
Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG
Liu, Vivian M. , Naru, Jasmine , Pogosova‐Agadjanyan, Era L. , Appelbaum, Frederick R. , Beppu, Lan , Chauncey, Thomas R. , Fang, Min , Moseley, Anna , Radich, Jerald P. , Wu, Feinan , Stirewalt, Derek L. , Othus, Megan , Ries, Rhonda E. , Erba, Harry Paul , Godwin, John E. , Fitzgibbon, Matthew , Lee, Stanley Chun-Wei , Willman, Cheryl L. , Meshinchi, Soheil

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4309-4309

10.1182/blood-2024-198506 Get It

NPM1 mutations (NPM1+) are found in about 30% of adult AML. While NPM1+ are generally associated with favorable risk, prior studies have shown that NPM1+ older patients, defined as ≥ 65 years, have significantly worse outcomes. The updated European Leukemia Net 2022 (ELN22) now classifies NPM1+ AML patients with FLT3-ITD (ITD+) and MDS-associated mutations (MDSm+) as adverse-risk, while NPM1+/ITD-/MDSm+ patients remain favorable-risk unless they have an adverse-risk karyotype. A recent report (Chan et al., Blood Adv 2024) found MDSm+ conferred worse OS only in patients ≥ 60 years; however another report (Othman et al., Blood 2024) did not find MDSm+ were significantly associated with adverse outcomes in a larger cohort of NPM1+ patients. To further assess this question, we examined the mutational landscape in a large cohort of pre-treatment, diagnostic specimens from 456 patients enrolled in SWOG clinical trials (SWOG-9031, SWOG-9333, S0106, and S0112) and 126 patients from the UW/FHCC Hematopoietic Repository (Total N=582). Patients were treated with curative intent as per standard practice or clinical trials. Out of the 582 patients, 191 were NPM1+ (33%), of which 148 patients had cytogenetic and long-term outcome data. Kaplan-Meier and cumulative incidence estimates were estimated. C-statistics and AUC for Cox, cause-specific and logistic regression models for overall survival (OS), event-free survival (EFS), time to relapse (TTR, calculated in n=106 who achieved complete remission [CR], death in remission analyzed as a competing risk) and CR were calculated for age, ELN17, and ELN22, as well as ELN17 and ELN22 adjusting for age. ELN17 favorable-risk patients reclassified as adverse-risk (N=5 of 108) demonstrated significantly shorter EFS (HR=2.50, p=0.05) and CR rate (OR=0.20, p=0.024), although with similar OS (HR 1.30, p=0.66) and TTR (HR=1.20, p=0.86). ELN17 favorable-risk patients reclassified as ELN22 intermediate-risk (N=23 of 108) did not show a significant difference in OS (HR 1.47, p=0.20), EFS (HR 1.35, p=0.12), CR rate (OR 0.75, p=0.46), or TTR (HR=1.64, p=0.11) compared to ELN22 favorable-risk. For ELN17 intermediate-risk (N=40), 5 patients were reclassified as ELN22 adverse-risk (12.5%) and had significantly shorter EFS (HR 2.89, p=0.037) compared to ELN22 intermediate risk, although there was not a significant difference in CR rate (OR 0.31, p=0.23) or OS (HR 0.81, p=0.67). We next compared the prognostic significance of age relative to ELN risk classification. Age was associated with higher C-statistics (OS=0.65, TTR=0.57 and EFS=0.60) and AUC (CR=0.64) compared to both ELN17 (OS=0.56, TTR=0.54, EFS=0.54, CR=0.54) or ELN22 (OS=0.57, TTR=0.57, EFS=0.57, CR=0.58). The combination of age and ELN22 resulted in the highest C-statistics for OS, TTR, and EFS (OS=0.68, TTR=0.60, EFS=0.64). To further assess the impact of MDSm on risk-stratification of NPM1+ AML, we performed multivariable analyses adjusting for FLT3-ITD, MDSm, and age in patients without adverse-risk disease. These analyses showed MDSm did not have a significant association with OS when controlling for age or FLT3-ITD. We also compared ELN22 favorable-risk patients with and without MDSm (MDSm+ N=18; MDSm- N=61). Compared with the MDSm-, there was a trend toward an inferior OS (HR 1.85, p=0.054) for MDSm+ patients but not EFS (HR 1.38, p=0.3) or TTR (HR 1.2, p=0.64). When stratified by age (<65, N=53 vs. ≥65, N=26), MDSm+ in younger patients did not show a difference for OS (HR 0.96, p=0.96), EFS (HR 0.63, p=0.53) or TTR (HR 0.4, p=0.37). Older ELN22 favorable-risk patients (≥65) had similarly poor OS (MDSm- HR 3.33 and MDSm+ 3.27, respectively, p=0.001 for both) and EFS (MDSm- HR 3.11 and MDSm+ 2.39, p=0.001 and 0.01) compared to younger MDSm- patients. In our study, the ELN22 guidelines incrementally improve risk stratification for EFS in NPM1+ patients. However, age remains the most prognostic factor, and patients ≥ 65 years have similar adverse clinical outcomes, whether classified as favorable risk by ELN17, ELN22, or incorporating MDSm. Moreover, MDSm do not confer a worse prognosis in NPM1+ patients when accounting for age or FLT3-ITD status. These findings differ from a recent report by Chan et al. and are in keeping with the report by Othman et al. Therefore, further understanding of the underlying biology of age and its effect on NPM1+ AML is needed to improve outcomes for older patients.
Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
Peres, Lauren C. , Richards, Alicia, Sidana, Surbhi , Oswald, Laura B. , Afrough, Aimaz , Shune, Leyla , Midha, Shonali , Castaneda, Omar, Ferreri, Christopher J. , Blue, Brandon , Ouchveridze, Evguenia, Bansal, Radhika , Smith, Kinaya, Avila, Gabriel De, Purvey, Sneha , Hosoya, Hitomi , Mikkilineni, Lekha , Gaballa, Mahmoud , Forsberg, Peter A. , Freeman, Ciara L. , Htut, Myo , Asoori, Sireesha, Kalariya, Nilesh, Atanackovic, Djordje , Dhakal, Binod , Khouri, Jack , Alsina, Melissa , Anderson, Larry D. , Martin, Thomas , Voorhees, Peter M. , Patel, Krina K. , Hansen, Doris K., Sborov, Douglas W. , Davis, James A. , Sidana, Surbhi , Anderson, Larry D , Davis, James A , Hosoya, Hitomi , Dima, Danai , Puglianini, Omar Castañeda , Davis, James A, Pasvolsky, Oren , Dillard, Christen , Herr, Megan M. , Kocoglu, Mehmet H. , Atrash, Shebli , Ouchveridze, Evguenia, McGuirk, Joseph P. , Wagner, Charlotte B , Costello, Patrick , Lieberman-Cribbin, Alex , Kaur, Gurbakhash , Janakiram, Murali , Dhakal, Binod , Raza, Shahzad , Reshef, Ran , Locke, Frederick L. , Nadeem, Omar , Anwer, Faiz , Richard, Shambavi , Lin, Yi , Hansen, Doris K.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3785-3785

10.1182/blood-2024-210078 Get It

*Authors contributed equally. Introduction. Two chimeric antigen receptor (CAR) T-cell therapies have been FDA approved for patients with relapsed/refractory multiple myeloma (RRMM): idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). Prior work from our consortium identified racial and ethnic differences in safety and response to ide-cel among patients treated in the standard of care (SOC) setting; despite these differences, survival was similar across race and ethnicity. Here, we extend this work to investigate racial and ethnic differences in safety, efficacy, and outcomes in a larger cohort of patients treated with SOC ide-cel with longer follow-up and patients treated with SOC cilta-cel. Methods. Data for RRMM patients who underwent leukapheresis by 12/31/2022 and were treated with SOC ide-cel or cilta-cel were pooled across 19 institutions in the U.S. Multiple Myeloma Immunotherapy Consortium. We compared Non-Hispanic White, Non-Hispanic Black, and Hispanic (any race) patients, excluding other racial and ethnic groups due to small sample sizes that precluded sub-group investigations. Separately for each CAR T-cell therapy, racial and ethnic differences in baseline patient characteristics, safety, and treatment responses were examined using chi-square and Kruskal-Wallis rank sum tests. Kaplan-Meier survival curves and log-rank tests were used to examine progression-free survival (PFS) and overall survival (OS) by race and ethnicity. Results. Among 332 RRMM patients treated with ide-cel, Non-Hispanic Black and Hispanic patients comprised 17% and 10% of the cohort, respectively. Hispanic patients were younger at infusion compared to Non-Hispanic Black and Non-Hispanic White patients (55.5 vs. 63 vs. 66 years, p<0.001). Non-Hispanic Black patients had a higher disease burden (≥ 50% bone marrow plasma cell percentage) compared to Non-Hispanic White and Hispanic patients (35% vs. 20% vs. 19%, p=0.05), while a higher proportion of Non-Hispanic White patients had high-risk cytogenetics compared to Non-Hispanic Black and Hispanic patients (37% vs. 23% vs. 10%, p=0.003). Non-Hispanic Black patients were more likely to develop severe (≥ grade 3) cytopenia at day 30 (p<0.001) and day 90 (p=0.01) post-infusion, and these differences were particularly driven by higher rates of severe neutropenia among Non-Hispanic Black patients at these time points. Non-Hispanic White patients were more likely to achieve a best response of partial response (PR) or better (82%) compared to Non-Hispanic Black (75%) and Hispanic patients (63%, p=0.02). No other racial and ethnic differences in baseline patient characteristics (including cytopenias), safety, PFS, and OS were observed (p>0.05). Among 222 RRMM patients treated with cilta-cel, Non-Hispanic Black and Hispanic patients comprised 12% and 9% of the cohort, respectively. At baseline, Non-Hispanic Black and Hispanic patients were more likely to have anemia (p=0.01), and Non-Hispanic Black patients were more likely to have thrombocytopenia (p=0.02) and neutropenia (p=0.06) compared to Non-Hispanic White patients. No other differences in baseline patient characteristics were observed by race and ethnicity. While not statistically significant, a higher rate of severe (≥ grade 3) cytopenia at day 90 post-infusion was observed among Non-Hispanic Black and Hispanic patients compared to Non-Hispanic White patients (33% vs. 44% vs. 21%, p=0.07), similar to the ide-cel cohort. This finding was primarily driven by higher rates of severe neutropenia among Non-Hispanic Black patients and higher rates of anemia among Hispanic patients. No other racial and ethnic differences in safety, responses to cilta-cel, PFS, or OS were not observed in the cilta-cel cohort (p>0.05). Conclusion. In a large cohort of RRMM patients treated with SOC ide-cel or cilta-cel, we observed a higher rate of cytopenias post-infusion and inferior ide-cel responses among racial and ethnic minority patients compared to Non-Hispanic White patients. Despite these differences, survival was similar across race and ethnicity, suggesting that both available CAR T-cell therapies for RRMM patients can be utilized across all populations. Future studies that include larger patient cohorts of racially and ethnically diverse patients should be conducted to confirm these findings and additionally evaluate long-term outcomes.
Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
Negaard, Brianna J, Chartier, Loïc , Guerra, Luca, Haddadi, Sara , Black, Harrison, Trevis, Thomas , Tong, Tsz Hung, Moalem, Kamilia , Johnston, Anna , Hampel, Paul J. , Johnson, Jeffrey S. , Elizabeth, Steinepreis, Yang, Pinguang, Kosciejew, Serena, Elizabeth, Gould, Manos, Kate , Nowakowski, Grzegorz S. , Hodges, Georgina, Flowers, Christopher R. , Lossos, Izidore S. , Ansell, Stephen M., Mondello, Patrizia , Gysbers, Brianna J. , Arcaini, Luca , Tobin, Joshua W.D. , Link, Brian K. , Feldman, Andrew L. , Chihara, Dai , Casulo, Carla , Cottereau, Anne-Ségolène , Olson, Joshua, Romancik, Jason T. , Black, Harrison, Mou, Eric , Cheah, Chan Y. , Salvaris, Ross , Habermann, Thomas M. , Martin, Peter, Kahl, Brad S. , Nastoupil, Loretta J. , Talaulikar, Dipti , Trotman, Judith , Cerhan, James R. , Burack, Richard , Luminari, Stefano , Morschhauser, Franck , Ansell, Stephen M. , Maurer, Matthew J.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3007-3007

10.1182/blood-2024-202088 Get It

Background: Positron emission tomography (PET) scan is the imaging modality of choice for initial staging and response assessment of follicular lymphoma (FL). Quantitative parameters such as standardized uptake value (SUV) have been investigated as putative prognosticators in FL, with high baseline SUVmax predicting aggressive disease. To date, there is no data to guide treatment choices in patients (pts) with high SUVmax but with no documented evidence of histologic transformation (HT). Specifically, it remains unclear whether anthracycline-containing regimens, such as R-CHOP, are more beneficial than R-Bendamustine (BR) in these pts. Therefore, we aimed to compare the efficacy of frontline R-CHOP and BR in newly diagnosed FL pts based on the SUVmax at baseline PET (bPET). Patients and Methods: Pts with newly diagnosed, biopsy-proven FL1-2 and FL3A who had a bPET scan and who received either first-line R-CHOP or BR within 6 months of diagnosis between 2002 and 2022 were evaluated. Analysis was restricted to pts with age < 70 years to reduce confounding of age with treatment selection. Cohorts included were the FOLL12 (n=562, Luminari et al JCO 2022) and the R-chemotherapy arm of the RELEVANCE (n=216, Morschhauser et al NEJM 2018) clinical trials, the prospectively enrolled Molecular Epidemiology Resource (MER) and the Lymphoma Epidemiology of Outcomes (LEO) cohorts (n=288) and a retrospective cohort from 13 Australian centers (n=219). Choice of chemotherapy regimen was per treating physician. Maintenance was per protocol (FOLL12/RELEVANCE) or per treating physician (MER/LEO/Australia). Event-free survival (EFS) and overall survival (OS) were defined as time from treatment initiation to progression, relapse, retreatment or death; both were censored at 72 months due to varying follow-up across cohorts. SUVmax was grouped by tertile within each cohort to account for potential differences in SUVmax distributions and patient populations across cohorts. Kaplan Meier curves and multivariable Cox models cohort-stratified and adjusted for clinical factors (FLIPI, ECOG PS, age, grade 3A) were used to evaluate outcomes. Results: The median age at diagnosis was 57 years (IQR 49-64). 651 (51%) pts were treated with R-CHOP and 634 (49%) with BR. Within the study cohorts, there was a prevalence of cases receiving BR compared to R-CHOP in the Australian (90% vs 10%) and MER/LEO (68% vs 32%) cohorts, while the opposite was observed in the RELEVANCE (16% vs 84%) and FOLL12 (37% vs 63; p<0.001) trials. Pts receiving R-CHOP were slightly younger (median 56 vs 58 years, p=0.005), more frequently had grade 3A (17% vs 7%, p<0.001), elevated LDH (27% vs 22%, p=0.029), bulky disease > 7 cm (44% vs 37%, p=0.019), lower ECOG PS (PS >1 7% vs 13%, p<0.001), and higher rate of high risk FLIPI (37% vs 30%, p=0.005). Baseline SUVmax was slightly lower in R-CHOP (median 10.7, IQR 7.9-14.9) vs BR (median 11.0, IQR 8.2-14.2) treated pts (p=0.0045). At a median follow-up of 56 months (range, 1-72 months), 415 pts (32%) had an event and 103 (8%) died. Higher SUVmax was not associated with EFS (middle tertile HR=0.96, 95% CI 0.76-1.22; upper tertile HR=0.86, 95% CI 0.68-1.09; p=0.45) or OS (middle tertile HR=1.28, 95% CI 0.80-2.05; upper tertile HR=0.97, 95% CI 0.59-1.59; p=0.44) in multivariable models stratified on cohort and adjusted for treatment and clinical factors. We then compared outcomes by treatment within tertiles of SUVmax. In multivariable models, R-CHOP had modestly inferior EFS to BR in low (HR=1.27, 95% CI 0.84-1.93) and middle tertiles (HR=1.49, 95% CI 0.99-2.25), and modestly superior OS to BR in low (HR=0.59, 95% CI 0.23-1.47) and middle (HR=0.79, 95% CI 0.37-1.71) tertiles. Both EFS (HR=1.06, 95% CI 0.71-1.58) and OS (HR=1.02, 95% CI 0.45-2.30) for R-CHOP were similar to BR in the highest tertile. No comparisons identified a statistically significant benefit for either therapy in multivariable models when evaluating SUVmax tertile subsets. Conclusions: In this large multicenter study of newly diagnosed FL pts with bPET who received frontline immunochemotherapy, higher baseline SUVmax was not associated with inferior outcomes after adjusting for treatment and clinical factors. Within the caveats of retrospective studies and confounding of treatment selection, these data provide no clear insights for SUVmax-based therapy selection in first-line follicular lymphoma pts treated with immunochemotherapy.